期刊文献+

宫颈癌组织中survivin和CD44v6的表达及其与HPV_(16/18)感染的相关性

Expression of survivin and CD44v6 in uterine cervical carcinoma and its association with HPV_(16/18) infection
下载PDF
导出
摘要 目的研究survivin、CD44v6在宫颈癌组织中的表达及其与HPV16/18感染的相关性,以探讨宫颈癌的发生机制。方法用免疫组化方法进行survivin和CD44v6的检测,用PCR检测HPV16/18感染情况。结果survivin和CD44v6的阳性率在宫颈癌组织中远高于CIN和正常宫颈组织,差异显著(均P<0.01),其表达率与淋巴结转移有关(均P<0.05)。CD44v6随着临床分期、病例分级的升高阳性率升高(P<0.05),survivin的阳性率则随着病例分级的升高而增加(P<0.05)。HPV16/18在正常宫颈组织、CIN和宫颈癌中的阳性率逐渐升高(P<0.01),但与临床分期、病理分级、淋巴转移无关。survivin与HPV16/18感染有相关性(P<0.05)。结论宫颈癌组织中survivin的异常表达与HPV16/18感染有关。survivin和CD44v6与宫颈癌的恶变程度有关,可作为宫颈癌筛查预后判断的有利指标。 Objective To investigate the relationship between expression of survivin and CD44v6 and HPV16/18 infection in uterine cervical carcinogenesis. Methods Using Streptavidin-Peroxidase (S-P) immunohistochemical technique, the authors examined the expression of survivin and CD44v6 in samples. The infection of HPV type 16, 18 DNA was determined by PCR. Results There were significant differences for survivin and CD44v6 between carcinomas, CIN and normal cervices (P 〈 0. 01, respectively). Expression of CD44v6 was correlated with tumor gradings, clinical stages and lymph node metastasis ( P 〈 0. 05 ) , and expression of survivin was associated with tumor grades and lymph node metastasis( P 〈0. 05 ). The positive rate of HPV16/18 was significant different among cervical carcinomas, CIN and normal tissues(P 〈0. 01 )but was not associated with tumor grading, clinical stages and lymph node metastasis. The infection of HPV16/18 was associated with the expression of survivin( P 〈 0. 05 ). Conclusion The abnormal expression of survivinis associated with the infection of HPV16/18. survivin and CD44v6 possibly become useful indexes for the primary screening and prognosis of cervical carcinomas.
出处 《基础医学与临床》 CSCD 北大核心 2007年第3期288-292,共5页 Basic and Clinical Medicine
基金 山西省科技厅自然基金(20051115)
关键词 SURVIVIN CD44V6 人乳头瘤病毒(HPV) 宫颈癌 survivin CD44v6 human papillomavirus( HPV) cervical carcinomas
  • 相关文献

参考文献9

  • 1连巧娟,林巧稚.妇科肿瘤学[M].3版.北京:人民卫生出版社,2000:209
  • 2Furumoto H, Irahara M. Human papillomavirus (HPV) and cervical cancer[J]. J Med Invest, 2002, 49(3-4):124-133.
  • 3Helliwell TR. Molecular markers of metastasis in squamous carcinomas[J]. J Pathol, 2001, 194(3):289-293.
  • 4Baay MF, Quint WG, Koudstaal J, et al. COmprehessive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffinembedded cervical carcinomas [ J ]. J Clin Microbiol,1996, 34(3) :745 -747.
  • 5Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin [ J ]. Nature,1998, 396(6711 ) :580 - 584.
  • 6Saitoh Y, Yaginuma Y, Ishikawa M, et al. Analysis of Bcl-2, Bax and survivin genes in uterine cancer [ J ]. Int J Onco, 1999, 15 ( 1 ) : 137 - 141.
  • 7Kim HS, Shiraki K, Rark SH, et al. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix [J]. Anticancer Res, 2002, 22(2A) :805 -808.
  • 8Frost M, Jarboe EA, Orlicky D, et al. Immunohistochemical localizaion of survivin in benign cervical mucosa, cervical dysplasia and invasive squamous cell carcinoma [ J ].Am J Clin Pathol,2002, 17(5) : 738 -744.
  • 9孙晓敏,董卫国,余保平,罗和生,于皆平.检测恶性腹水中VEGF、CD44v6和MMP-2、MMP-9的临床意义[J].癌症,2004,23(1):85-89. 被引量:16

二级参考文献11

  • 1[1]Kleiner DE, Stetler-Stevenson WG. Quantitative zymography:detection of picogram quantities of gelatinases[J]. Anal Biochem, 1994, 218(2): 325 - 329.
  • 2[2]Young TN, Rodriguz GC, Rinehart AR, et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2[J].Gynecologic Oncology, 1996, 62 ( 1 ): 89 - 99.
  • 3[3]Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusion of patients with malignant and nonmalignant disease [ J ]. Cancer, 1999, 85 ( 1 ): 178 - 187.
  • 4[4]Mori A, Arii S, Furutani M, et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes[J]. Gene Therapy, 2000, 7(12): 1027-1033.
  • 5[5]Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites[J]. Ann Sury Oncol, 1999,6(4), 6:373 - 378.
  • 6[6]Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer[J]. Cancer Research, 2002, 62(2):2019-2023.
  • 7[7]Peterson RM, Yu Q, Stamenkovic I, et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites[J]. American Journal of Pathology, 2000; 156(6): 2159 - 2167.
  • 8[8]Fishman DA, Bafetti LM, Banionis S, et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells[J]. Cancer, 1997, 80(3): 1457 - 1463.
  • 9[9]Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase 1 study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions[J].Clinical Cancer Research, 1999, 5 (3): 513 - 520.
  • 10[10]Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling, s law of capillary hemodynamics revisited[J].Annals of Oncology, 2001, 12(10): 1353 - 1357.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部